Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 73

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Pharmacokinetics of the CYP 3A Substrate Simvastatin following Administration of Delayed Versus Immediate Release Oral Dosage Forms

Tubic-Grozdanis, Marija, Hilfinger, John M., Amidon, Gordon L., Kim, Jae Seung, Kijek, Paul, Staubach, Petra, Langguth, Peter·2008·Pharmaceutical Research
DOI 10.1007/s11095-007-9519-6
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s11095-007-9519-6

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 44

  1. P. Watkins. Drug metabolism by cytochromes P450 in the liver and small bowel. Gastroenterol. Clin. North Am. 21:511–526 (1992). · DOI
  2. Q. Zhang, D. Dunbar, A. Ostrowska, S. Zeisloft, J. Yang, and L. Kaminsky. Characterization of human small intestinal cytochromes P-450. Drug Metab. Dispos. 27:804–809 (1999). · DOI
  3. R. McKinnonand, and M. McManus. Localization of cytochromes P450 in human tissues: Implications for chemical toxicity. Pathology 28:148–155 (1996). · DOI
  4. M. Thorn, N. Finnstrom, S. Lundgren, A. Rane, and L. Loof. Cytochromes P450 and MDR1 mRNA expression along the human gastrointestinal tract. Br. J. Clin. Pharmacol. 60:54–60 (2005). · DOI
  5. O. von Richter, O. Burk, M. Fromm, K. Thon, M. Eichelbaum, and K. Kivistö. Cytochrome P450 3A4 and P-glycoprotein expression in human small intestinal enterocytes and hepatocytes: a comparative analysis in paired tissue specimens. Clin. Pharmacol. Ther.172–183 (2004). · DOI · Paper page
  6. A. Basit. Advances in colonic drug delivery. Drugs 65:1991–2007 (2005). · DOI
  7. D. R. Friend. Oral colon-specific drug delivery, CRC Press, Boca Raton, FL, 1992.
  8. G. Patel. Oral colon-specific drug delivery: an overview. Drug Delivery Techno. 6:62–71 (2006).
  9. T. Prueksaritanont, B. Ma, and N. Yu. The human hepatic metabolism of simvastatin hydroxy acid is mediated primarily by CYP3A, and not CYP2D6. Br. J. Clin. Pharmacol. 56:120–124 (2003). · DOI · Paper page
  10. A. Tornio, M. Pasanen, J. Laitila, P. Neuvonen, and J. Backman. Comparison of 3-hydroxy-3-methylglutaryl Coenzyme A (HMG-CoA) reductase inhibitors (statins) as inhibitors of cytochrome P450 2C8. Basic Clin. Pharmacol. Toxicol. 97:104–108 (2005). · DOI
  11. C. Transon, T. Leemann, and P. Dayer. In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors. Eur. J. Clin. Pharmacol. 50:209–215 (1996). · DOI
  12. J. Hilfinger, J. Kim, and P. Kijek. Methods and composition of extended delivery of water insoluble drugs. In U. P. A. Publication (ed.) (U. P. A. Publication, ed.), USA, 2005.
  13. L. Schmuff. HPLC Method for Pharmaceutical Analysis. John Willey & Sohns, New York, 1997.
  14. J. Zhao, I. H. Xie, A. Yang, B. Roadcap, and J. Rogers. Quantitation of simvastatin and its ß-hydroxy acid in human plasma by liquid–liquid cartridge extraction and liquid chromatography/tandem mass spectrometry. J. Mass Spectrom. 35:1133–1143 (2000). · DOI
  15. M. Gibaldi, and D. Perrier. Pharmacokinetics. Marcel Dekker, New York, 1982. · DOI
  16. I. Mahmood. Pharmacokinetic analysis of the absorption characteristics of diclofenac sodium in man by use of a multi-segment absorption model. J. Pharm. Pharmacol. 48:1260–1263 (1996). · DOI
  17. H. Cheng, J. Rogers, A. Sweany, M. Dobrinska, E. Stein, A. Tate, R. Amin, and H. Quan. Influence of age and gender on the plasma profiles of 3-hydroxy-3-methylglutaryl-Coenzyme A (HMG-CoA) reductase inhibitory activity following multiple doses of lovastatin and simvastatin. Pharm. Res. 9:1629–1633 (1992). · DOI
  18. M. Kaufman. Applications of oxygen polarography to drug stability testing and formulation development: solution-phase oxidation of hydroxymethylglutaryl Coenzyme A (HMG-CoA) reductase inhibitors. Pharm. Res. 7:289–292 (1990). · DOI
  19. M. Ozyazici, E. Gokce, and G. Ertan. Release and diffusional modeling of metronidazole lipid matrices. Eur. J. Pharm. Biopharm. 63:331–339 (2006). · DOI
  20. V. Jannin, E. Pochard, and O. Chambin. Influence of poloxamers on the dissolution performance and stability of controlled-release formulations containing Precirol ATO 5. Int. J. Pharm. 309:6–15 (2006). · DOI
  21. M. Savolainen, C. Khoo, H. Glad, C. Dahlqvist, and A. Juppo. Evaluation of controlled-release polar lipid microparticles. Int. J. Pharm. 244:151–161 (2002). · DOI
  22. P. Parab, C. Oh, and W. Ritschel. Sustained release from Precirol (glycerol palmito-stearate) matrix: effect of mannitol and hydroxypropyl methylcellulose on the release of theophylline. Drug Dev. Ind. Pharm. 12:1309–1327 (1986). · DOI
  23. M. Savolainen, J. Herder, C. Khoo, K. Lovqvist, C. Dahlqvist, H. Glad, and A. Juppo. Evaluation of polar lipid-hydrophilic polymer microparticles. Int. J. Pharm. 262:47–62 (2003). · DOI
  24. J. Sousa, A. Sousa, M. Moura, F. Podczeck, and J. Newton. The influence of core materials and film coating on the drug release from coated pellets. Int. J. Pharm. 233:111–122 (2002). · DOI
  25. H. Stevens, C. Wilson, P. Welling, M. Bakhshaee, J. Binns, A. Perkins, M. Frier, E. Blackshaw, M. Frame, and D. Nichols. Evaluation of Pulsincap to provide regional delivery of dofetilide to the human GI tract. Int. J. Pharm. 236:27–34 (2002). · DOI
  26. D. Bailey, J. Kreeft, C. Munoz, D. Freeman, and J. Bend. Grapefruit juice-felodipine interaction: Effect of naringin and 6. ,7. -dihydroxybergamottin in humans. Clin. Pharmacol. Ther. 64:284–256 (1998). · DOI
  27. A. Kashuba, J. J. Bertino, M. Rocci, R. Kulawy, D. Beck, and A. Nafziger. Quantification of 3-month intraindividual variability and the influence of sex and menstrual cycle phase on CYP3A activity as measured by phenotyping with intravenous midazolam. Clin. Pharmacol. Ther. 64:269–277 (1998). · DOI
  28. E. Kharasch, M. Russell, K. Garton, G. Lentz, T. Bowdle, and K. Cox. Assessment of cytochrome P450 3A4 activity during the menstrual cycle using alfentanil as a noninvasive probe. Anesthesiology 87:26–35 (1997). · DOI
  29. J. Scavone, D. Greenblatt, A. Locniskar, and R. Shader. Alprazolam pharmacokinetics in women on low-dose oral contraceptives. J. Clin. Pharmacol. 28:454–457 (1988). · DOI
  30. G. Stoehr, P. Kroboth, R. Juhl, D. Wender, J. Phillips, and R. Smith. Effects of oral contraceptives on trizolam, temazepam, alprazolam, and lorazepam kinetics. Clin. Pharmacol. Ther. 36:683–690 (1984). · DOI
  31. H. Lennernäs, and C. Regardh. Evidence for an interaction between the beta-blocker pafenolol and bile salts in the intestinal lumen of the rat leading to dose-dependent oral absorption and double peaks in the plasma concentration-time profile. Pharm. Res. 10:879–883 (1993). · DOI
  32. M. Flash-Ner-Barak, I. Lerner, V. Rosenberger, and N. Moldavski. Simvastatin formulations and methods of making same. In T. p. i. ltd. (ed.), Vol. WO 2005/044254 A1 (T. p. i. ltd., ed.), Israel, 2005, pp. 1–32.
  33. T. N. Tozerand, and M. Rowland. Introduction to Pharmacokinetics and Pharmacodynamics: The Quantitative Basis of Drug Therapy. Lippincott Williams & Wilkins, USA, 2006.
  34. J. Kolars, K. Lown, P. Schmiedlin-Ren, M. Ghosh, C. Fang, S. Wrighton, R. Merion, and P. Watkins. CYP3A gene expression in human gut epithelium. Pharmacogenetics 4:247–259 (1994). · DOI
  35. O. Mousa, D. Brater, K. Sundblad, and S. Hall. The interaction of diltiazem with simvastatin. Clin. Pharmacol. Ther. 67:267–274 (2000). · DOI
  36. K. Thummel, D. O’Shea, M. Paine, D. Shen, K. Kunze, J. Perkins, and G. Wikinson. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin. Pharmacol. Ther. 59:491–502 (1996). · DOI
  37. J. Lilja, K. Kivisto, and P. Neuvonen. Grapefruit juice-simvastatin interaction: effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors. Clin. Pharmacol. Ther. 64:477–483 (1998). · DOI · Paper page
  38. H. Benameur, V. Jannin, and D. Roulot. Method and formulation for decreasing statin metabolism. In F. Gattefosse Holding (ed.), Vol. US 6,652,865 B2 (F. Gattefosse Holding, ed.), USA, 2003.
  39. W. Homsy, G. Caille, and P. du Souich. The site of absorption in the small intestine determines diltiazem bioavailability in the rabbit. Pharm. Res. 12:1722–1726 (1995). · DOI
  40. M. Pasanen, M. Neuvonen, P. Neuvonen, and M. Niemi. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenetics and Genomics 16:873–879 (2006). · DOI · Paper page
  41. M. Davidson. A look to the future: new treatment guidelines and a perspective on statins. Am. J. Med. 112 (Suppl 8A):34S–41S (2002). · DOI
  42. M. Davidson, P. Lukacsko, J. Sun, G. Phillips, E. Walters, A. Sterman, R. Niecestro, and L. Friedhoff. A multiple-dose pharmacodynamic, safety, and pharmacokinetic comparison of extended- and immediate-release formulations of lovastatin. Clin. Ther. 24:112–125 (2002). · DOI
  43. B. Hamelinand, and J. Turgeon. Hydrophilicity/lipophilicity:relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors. TiPS 19:26–37 (1998).
  44. T. Sawada, K. Sako, K. Yoshihara, K. Nakamura, S. Yokohama, and M. Hayashi. Timed-release formulation to avoid drug–drug interaction between diltiazem and midazolam. J. Pharm. Sci. 92:790–797 (2003). · DOI

Cited by

See all 73

Metadata

Authors
Tubic-Grozdanis, M., Hilfinger, J. M., Amidon, G. L., Kim, J. S., Kijek, P., Staubach, P., & Langguth, P.
Venue
Pharmaceutical Research
Publisher
Springer Science and Business Media LLC
Published
2008-01-24
Volume
25
Issue
7
Pages
1591-1600
ISSN
  • 0724-8741
  • 1573-904X
DOI
10.1007/s11095-007-9519-6
Cited by
73
References
1
Language
en
Licence
www.springer.com/tdm (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.